Merrimack Pharma’s stock plunges (again) on its latest cancer drug trial flop

Merrimack Pharmaceuticals $MACK has another loser on its hands.

The drug MM-121 (seribantumab) added to docetaxel did not do any better than docetaxel alone in improving the progression-free survival of patients suffering from non-small cell lung cancer.